Journal of Tropical Diseases & Public Health

Université Ouaga 1 Pr Joseph Ki Zerbo, Burkina Faso, West Africa

Biography

Dr. Yves Traoré Managing Director, Sysmex Partec Burkina Faso. He already served at COO, Partec West Africa SARL, Burkina Faso. He is associated to the research area of Infection, Malaria, Plasmodium, Vaccines, Flow Cytometry, Immunology, Infectious Diseases, Immunology of Infectious Diseases

Publications

• Research   
  Antibody and P. falciparum Parasites Profiles during Clinical Malaria Episodes Following Artemisinin-Based Combination Therapy in Burkina Faso
  Author(s): Fatimata Thiombiano, San Maurice Ouattara, Aboubacar Coulibaly, Guillaume Sylvestre Sanou, Moïse Kaboré, Amidou Diarra, Issiaka Soulama, Yves Traoré, Sodiomon Bienvenu Sirima and Issa Nébié*
  
  Background: Artemisinin-based Combination Therapies (ACTS) are the first recommended drug for uncomplicated malaria treatment in many endemic countries. They are responsible for rapid parasites clearance and in reducing fever. Artemisinin has been found to have an immunosuppressive effect in animal’s models. In the present study, we assessed the effect of ACTs on malaria antigens specific antibodies production during subsequent malaria episodes in a population living in malaria hyperendemic area. Methods: In 2012, 371 patients with, presenting uncomplicated clinical malaria aged over 6 months and adults were recruited and allocated to receive ACTs and follow up for 2 years. Antibodies titers against three P. falciparum blood stage malaria vaccine candidates (MSP3, GLURP R0, and GLURP R2) were measured by ELISA during subsequen.. View more»
  

  Abstract PDF